[CLSTR]
< Back to situations

[ORGANIZATION]

Agenzia Italiana del Farmaco

Featured in 11 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [IT]

Italy influenza, COVID-19 and RSV vaccination rollout

21 clusters · 196 sources · last updated

Latest: Italy expands influenza and Covid-19 vaccination access

The 2026-2027 seasonal vaccination campaign in Italy, targeting influenza, COVID-19, and Respiratory Syncytial Virus (RSV), is underway following preparations in September. Ahead of the October rollout, the Italian Medic

[ACTIVE] [HEALTH] [IT]

AIFA pharmaceutical innovation and evaluation discussions

2 clusters · 9 sources · last updated

Latest: AIFA President Nisticò discusses pharmaceutical innovation and drug authorization

The Italian Medicines Agency (AIFA) has initiated institutional dialogues focused on the value of pharmaceutical innovation and its impact on the Italian National Health Service. During a conference in Genoa, discussions

[QUIET] [POLITICS] [IT]

Basilicata confirms Oct 16 start for pharmaceutical fee

5 clusters · 15 sources · last updated

Latest: Basilicata approves new pharmaceutical co-payment exemptions

Following the implementation of the 2.50 euro pharmaceutical co-payment on September 1, 2026, the Basilicata region has entered a period of heightened social and political tension. While the regional government maintains

[QUIET] [HEALTH] [IT]

Medical advancements and drug approvals in Italy

2 clusters · 23 sources · last updated

Latest: AIFA approves Mirikizumab reimbursement for Crohn's disease in Italy

Medical developments in Italy have recently focused on advancements in respiratory medicine and gastroenterology. During the XXVII National Congress of the Italian Society of Pulmonology (SIP/IRS) in Rome, experts discus

[QUIET] [HEALTH] [IT]

Advancements in Italian oncology and radiotherapy

4 clusters · 34 sources · last updated

Latest: Italy advances leukemia treatment through immunotherapy and integrated care models

Italian medical institutions continue to advance oncology through specialized training, genomic profiling, and personalized care models. To support genomic cancer profiling for approximately 15,000 eligible patients annu

Also covered in